Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 2.0 pts less than its Diversified Commercial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Johnson Pharmacare Ltd approved the unaudited financial results for the quarter ended 30 June 2025. The company reported zero revenue from operations in Q1 FY26, same as Q1 FY25, with no operating income whatsoever. The company posted a net loss of Rs. 5.34 lakhs for Q1 FY26, slightly wider than the Rs. 3.99 lakh loss in Q1 FY25. Total expenses stood at Rs. 5.34 lakhs, mainly employee costs (Rs. 0.30 lakh) and other expenses (Rs. 5.04 lakhs). For reference, the full year ended March 2025 showed a net loss of Rs. 58.38 lakhs, which included exceptional items of Rs. 17.16 lakhs. The statutory auditor (Rishi Sekhri and Associates) issued a clean limited review report with no qualifications.
The company is generating no operating revenue and continues to report losses, though the absolute loss amounts are small relative to its Rs. 5,500 lakh equity base. Shareholders should note the lack of any business activity or revenue stream, which raises concerns about the company's commercial viability and future plans despite the clean auditor review.